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Tumour angiogenesis and cellular pH regulation, mainly represented by Na
þ/H
þ antiporter exchange, have been heretofore
considered unrelated subfields of cancer research. In this short review, the available experimental evidence relating these areas of
modern cancer research is introduced. This perspective also helps to design a new approach that facilitates the opening and
development of novel research lines oriented towards a rational incorporation of anticancer drugs into more selective and less toxic
therapeutic protocols. The final aim of these efforts is to control cancer progression and dissemination through the control of tumour
angiogenesis. Finally, different antiangiogenic drugs that can already be clinically used to this effect are briefly presented.
British Journal of Cancer (2003) 89, 1395–1399. doi:10.1038/sj.bjc.6601286 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: angiogenesis; Na
þ/H
þ antiporter; pH regulation; oncogenesis; antiangiogenesis
                                  
Increasing attention is being paid to the Na
þ/H
þ antiporter
activity and/or to cell dynamics of the hydrogen ion (H
þ)i n
different areas of cancer research, at both the basic and clinical
levels. These attempts are mainly based upon the key role that both
H
þ ion transport and/or intracellular pH (pHi) play in multiple
aspects of the biology of tumour cells. It has long been
demonstrated that elevations in pHi are directly correlated with
the activity of many growth factors and oncogenes, DNA synthesis,
cell transformation and proliferation, the metastatic process
and multiple drug resistance (MDR) (Harguindey et al, 1995).
On the contrary, cytosolic hyperacidification is a generalised
event in programmed cell death at different stages of the apoptotic
process, while systemic acidification has been repeatedly con-
sidered to be related in a cause — effect manner to the
spontaneous regression of human cancer in both animals and
humans (Harguindey et al, 1995; Matsuyama et al, 2000; Rich et al,
2000). The latest research in these areas has shown cause — effect
relationships between cellular proton dynamics and Na
þ/H
þ
exchanger at different levels of the neoplastic process, from
oncogenesis to multiple drug resistance and from cancer regres-
sion to treatment.
In this review, we present the most recent and pertinent
data showing how these phenomena are related to the patho-
genesis and biology of tumour angiogenesis and antiangiogenesis.
In an attempt to integrate these subfields, the genetic and
microenvironmental aspects of both stimulatory and inhi-
bitory pathways shared by these areas of cancer research are
considered.
ANGIOGENESIS AND HYDROGEN ION DYNAMICS
Since the seminal work by Folkman (1971), it has been well
established that unrestricted growth of malignant tumours
requires the induction of new capillary blood vessels. This new
vessel formation plays a key role not only in tumour growth but
also in invasion and metastasis (Liotta et al, 1974). In fact,
angiogenesis enhances entry of tumour cells into the circulatory
system by providing an increased density of immature and highly
permeable blood vessels with little basement membrane and fewer
junctional complexes than normal mature vessels (Liotta et al,
1974). Moreover, increasing experimental evidence suggests that
tumoural angiogenesis is directly related to size, grade, invasive
behaviour and clinical outcome of several neoplastic diseases.
These range from breast cancer (Weidner et al, 1991) to non-
small-cell lung cancer (Macchiarini et al, 1992), melanoma (Foss
et al, 1996) and gastric cancer (Maeda et al, 1995).
The development of new blood vessels is a complex process
involving regulation of gene function and extensive interactions
between cells, soluble factors and extracellular matrix components.
Interestingly, some of these events also play a significant role in the
regulation of the hydrogen ion dynamics of tumour cells, a feature
that allows the drawing of close parallelisms between the
neovascularisation process and the regulation of intracellular
acid–base homeostasis. It is well recognised that pathological
elevations of pHi induce many specific biological and functional
characteristics of malignant cells such as neoplastic transforma-
tion, increases in cell detachment, motility, proliferation, perme-
ability and many others (Harguindey et al, 1995; Reshkin et al,
2000). Indeed, each of these features on its own is an essential step
in the formation of a pathological neovasculature network out of
pre-existing normal vessels. Notwithstanding these experimental
data, it still remains unclear to which degree and at which points
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Oncogenes and tumour-suppressor genes
The induction and maintenance of a tumour blood vessel are
largely attributed to the production of angiogenic factors by
malignant cells, a process governed by dominantly acting
oncogenes (Rak et al, 1995). Switching on of a tumour angiogenic
programme is triggered as a result of a shift in the balance of
stimulating factors induced by oncogenes and inhibiting factors
produced by tumour-suppressor genes. It has been demonstrated
that some oncogenes alter cell H
þ dynamics through an increase
in pHi, mainly as the result of the activation of membrane-bound
Na
þ/H
þ antiporter (Grunicke et al, 1988). For example, there is a
close association between ras oncogene expression, modulation of
angiogenesis in multiforme glioblastoma and the induction and/or
upregulation of vascular endothelial growth factor/vascular
permeability factor (VEGF/VPF). Overexpression of VEGF/VPF is
also correlated with the action of the H-ras gene product p21 in
advanced gastric carcinomas (Kim et al, 2000). Similarly, the Ha-
ras oncogene directly contributes to tumour development and
progression of epidermal tumours through increasing neovascu-
larisation. It has long been recognised that H-ras p21 and Ha-ras,
acting via a common pathway upon cell H
þ dynamics, result in
cellular alkalinisation and neoplastic transformation, while the
proto-oncogene form of Ha-ras, which does not raise pHi, induces
only a weak mitogenic response (Doppler et al, 1987).
Indeed, a pathological cellular alkalinisation has even been
deemed to represent the primary and pivotal factor responsible for
neoplastic transformation in different settings, at both the basic
and clinical levels (Harguindey et al, 1995). It is highly significant
that this cellular acid–base shift has been recently considered to be
the fundamental and specific derangement in cell transformation
and cancer aetiopathogenesis (Reshkin et al, 2000). Furthermore,
in NIH 3T3 fibroblasts expressing the Ha-ras oncogene, pHi was
found to be significantly more alkaline than in identical cells not
expressing the oncogene (Grunicke et al, 1988). This alkalinisation
has been considered to be driven mainly not only by the activation
of the Na
þ/H
þ exchanger, but also by Na
þ,K
þ and Cl
 -
cotransport systems.
Similarly, loss of function of tumour-suppressor genes leads to
the deregulation of cell growth, an event thought to play an
outstanding role in the development and progression of a high
percentage of human malignancies (Ferreira et al, 1999). p53 is a
classical tumour-suppressor gene. More than 50% of spontaneous
human cancers have either lost or mutated p53 function. This gene
is known to have many roles, including cell genome protection, cell
cycle arrest, facilitating apoptosis and sensitising tumour cells to
chemotherapy. It is thought that p53 performs all these different
functions by acting as a molecular stress-responsive device. p53
opposes tumour angiogenesis at various levels; for instance, it
inhibits the expression of VEGF and enhances the effect of
thrombospondin-1, a powerful inhibitor of angiogenesis (Ferreira
et al, 1999).
The importance of alterations and/or inactivation of p53 has
prompted the scientific community to try to answer some of the
questions involving the regulation of this gene, mainly why p53 is
prone to so many mutations and how the resulting genetic
deregulation can be avoided. Recent work by DiGiammarino et al.
(2002) seems to have shed significant light in this aspect. These
authors studied a group of children in southern Brazil exhibiting
an elevated incidence of adrenocortical carcinoma. Out of 36
children with this malignancy, 35 were found to harbour an Arg-
to-His mutation within the 337 tetramerisation domain of p53,
which appears to be necessary for the gene to function as a
regulator of cell cycle control and in the induction of apoptosis.
Apparently, the mutant tetramerisation domain is less stable than
the wild type, being highly sensitive to pH changes in the
physiological range. This pH sensitivity led the authors to suggest
that the increased pHi detected in these tumours is the final
molecular mechanism responsible for the destabilisation and loss
of p53 function and subsequent tumour development.
Hormonal and pharmacological regulators of angiogenesis
A certain number of positive regulators of angiogenesis have
been purified over the last few years (Folkman and Klagsbrun,
1987; O’Really et al, 1994, 1997). While these substances
influence virtually every aspect of the angiogenic cascade, many
of them have overlapping and sometimes opposing functions. The
pHi is very sensitive to the response cascade resulting from
different factors; in fact, Na
þ/H
þ antiport-mediated cytosolic
alkalinisation is induced by some of these upregulators
(Harguindey et al, 1995).
Interestingly, many of these angiogenic regulators have been
observed to have a direct effect on cell acid–base homeostatic
mechanisms, all of them in the same alkaline direction (Table 1) .
Among these, the proinflammatory cytokine IL-1 elevates pHi in T
cells through activation of the Na
þ/H
þ antiporter by a mechan-
ism that may involve protein kinase C (Civitelli et al, 1989). IL-1
also has numerous effects on the pathogenesis of tissue injury,
upregulating the VEGF-KDR/flk-1 system via activation of tyrosine
kinases and increasing transcription in both human proximal
tubular cells (El-Awad et al, 2000) and human colon cancer cells
(Akagi et al, 1999). This suggests an important role for IL-1 in the
process of angiogenesis both in tumour cells and ischaemic hearts
(Maruyama et al, 1999).
Hepatocyte growth factor (HGF) is another proangiogenic
molecule that also induces a pH elevation in primary cultured
hepatocytes by stimulating the Na
þ/H
þ antiporter through a
tyrosine kinase–calcium/calmodulin-dependent pathway. Besides
its effect on cellular H
þ dynamics, HGF is closely associated with
angiogenesis through its ability to stimulate endothelial cell
chemotaxis by inducing the expression of both VEGF and IL-8
(Dong et al, 2001) as well as the expression of the Tie-2 receptor
ligand and angiopoietin-2. Finally, angiotensin II is another
hormone that upregulates VEGF-KDR/flk-1 expression in retinal
microcapillary endothelial cells, neuro-2A cells and bovine retinal
pericytes, while at the same time also activating the Na
þ/H
þ
antiporter isoform-1 (NHE-1) (Kusuhara et al, 1998).
In spite of the fact that most of the angiogenic factors described
in Table 1 increase pHi through stimulation of the Na
þ/H
þ
antiporter, further research is still needed to fully elucidate the
exact mechanism by which angiogenic factors modulate the
activity of Na
þ/H
þ antiporters.
Migration and proliferation of endothelial cells
Endothelial cells (ECs) on the inner surface of blood vessels are
normally quiescent, maintaining the integrity of the vessels in the
adult. However, when these cells are stimulated by angiogenic
mediators, they gain the ability to form neovessels. In this way, the
neomorphogenetic creation of vessels influences the tumour
microenvironment and vice versa, giving rise to rapidly growing
vascularised tumours and thereby facilitating tumour spread and
the formation of metastatic colonies. The granulocyte- and
granulocyte–macrophage-colony-stimulating factor stimulates
motility of ECs and leucocytes and this has been demonstrated
to be dependent on a functional NHE1 (Denker and Barber, 2002).
In fact, among the six family members of the NHE antiporter, the
NHE-1 isoform is ubiquitously expressed and plays a key role in
pHi regulation and cell-volume homeostasis (Putney et al, 2002).
Remodelling of the extracellular matrix (ECM) is a prerequisite
for the formation of new vessels. In this vein, angiogenesis shows
several functional similarities to the process of tumour cell
H
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attachment during migration and the requirement of protease-
mediated remodelling of ECM. Some of the events that also affect
H
þ dynamics are:
Proteases Degradation of ECM is mediated by a large number of
proteases, a process where plasmin and plasminogen activators
(PA) play an outstanding role. Urokinase-type plasminogen
activator (mPA) is a PA that cleaves plasminogen to plasmin, a
glycoprotein with a high proteolytic activity. This process affects
EC adhesion and migration. It has been demonstrated that
amiloride, an NHE-1 blocker, is a powerful inhibitor of angiogen-
esis, being able to suppress both in vitro and in vivo the invasive
capacity of human breast cancer cells, at least in part through the
inhibition of mPA activity (Evans and Sloan-Stakleff, 2000).
Cathepsins are another family of proteases thought to be
important in the process of ECM degradation (Turk et al, 2002).
While degrading ECM, they release growth factors from the matrix
only when the extracellular environment is acidic, prompting
many to question their biological significance. Tumours are known
to have a more acidic extracellular microenvironment than normal
tissues. This is probably created and maintained to a large extent
by specific plasma membrane ion transporters, particularly NHE-
1. The intracellular microenvironment where the cell is in contact
with the ECM reaches very low pH levels thus facilitating the action
of the acidic proteases (Webb et al, 2001). Interestingly, lowering
of extracellular pH or the inhibition of transporters that alkalinise
the cell (particularly the NHE-1) has been demonstrated to
increase the secretion of cathepsin B in tumour cells (Rozhin
et al, 1994). This feature suggests a positive feedback as a
compensatory mechanism to keep protease activity high in
less optimal conditions. We have also found that cathepsin D
release was greatly increased by the same experimental protocols
(data not shown).
Integrins Endothelial cells attach to their underlying basement
membrane through integrin receptors that bind ECM proteins.
Cell proliferation and migration rely on the capacity of ECs to
move along their basement membrane. It is known that ECs,
as well as tumour cells under mitogenic stimulation, employ
their avb3 and avb5 receptors to migrate on vitronectin and
fibronectin. Furthermore, avb3 can inhibit angiogenesis, suggesting
that these receptors are crucial in angiogenesis (Eliceiri
and Cheresh, 2001). In addition, adhesion of EC integrins to
ECM components has been reported to result in significant
elevations of pHi leading some authors to conclude that
elevation of intracellular pH is a general property shared by many
members of the integrin family. In the same line, it has been
demonstrated that integrin activation stimulates cellular adhesion
and spreading and that this can be blocked by specific inhibition
of the NHE-1.
The trans-activation of growth factor receptors by integrins is an
emerging field. Recently, an interesting study showed that cell
adhesion, presumably through integrins, activates the human HGF
receptor, c-Met, while overexpression of c-Met in hepatocytes
resulted in hepatocellular carcinoma in mice (Wang et al, 2001).
Most significantly, this effect of c-Met is independent of binding of
HGF, suggesting that integrin-dependent trans-activation could
be responsible for tumourigenesis. Thus, trans-activation of
growth factor receptors by integrins may lead to dysregulated
cellular growth.
ANTIANGIOGENEIC MOLECULES AND CELLULAR
ACID–BASE HOMEOSTASIS
Antiangiogenesis may be defined as the inhibition of new blood
vessel formation and growth. The present day growing interest and
excitement surrounding antiangiogenesis as a novel approach to
anticancer therapy largely originates from the expectation that
anti-angiogenenic agents will eventually be selective in inhibiting
the formation of tumour vasculature and/or stimulating its
collapse, thus become specifically effective against a wide variety
of tumours. Since the first successful clinical treatment along this
line, several angiogenic inhibitors are being evaluated in clinical
trials for their efficacy as anticancer agents (Kerbel and Folkman,
2002). Significantly, while many proangiogenic molecules stimu-
late Na
þ/H
þ antiporter activity and/or increase cell pH, several
antiangiogenic agents have been shown to act, directly and/or
indirectly, on cellular hydrogen ion dynamics, resulting in a
tendency towards cell acidification (Table 2).
Suramin is an H
þ-ATPase inhibitor that represents a new type
of antitumour agent. This drug appears to interfere with multiple
steps and mediators involved in angiogenesis. Suramin has been
demonstrated to present antitumour activity in patients with
Kaposi ´s sarcoma, non-Hodkin ´s lymphoma, renal carcinoma,
adrenal carcinoma and hormone refractory prostate carcinoma.
In fact, patients with prostate carcinoma receiving suramin have
been reported to present a survival advantage over other phase II
trials drugs in prostate carcinoma (Clark and Chabner, 1995).
Although its exact mechanism remains unclear, suramin, as well as
other similar drugs, may ultimately work through a pH-related
mechanism, as has been suggested in the past.
Squalamine is another new, selective and noncytotoxic inhibitor
of new blood vessel formation. This antimicrobial aminosterol is
Table 1 Effect of angiogenic regulations on cell acid–base homeostatic mechnisms
Factor Effects on angiogenesis Effects on i.c. hydrogen ion dynamics
IL-1 Upregulates VEGF/VPF and KDR/flk-1 expression m H
+-ATPasa and Na
+/H
+ APA
IL-8 m EC migration and proliferation m i.c. pH and cytoplasmic-free Ca
2+
EGF m EC DNA synthesis, proliferation and migration m Na
+/H
+ APA
PDGF m EC DNA synthesis, proliferation and migration m Na
+/H
+ APA
G-CSF m EC DNA synthesis, proliferation and migration m i.c. pH elevation through m Na
+/H
+ APA
GM-CSF m activation/differentiation programme related to angiogenesis m Na
+/H
+ APA
TNF-a m EC migration m Na
+/H
+ APA
HGF/SF m tumour survival and proliferation m i.c. pH elevation
TGF-b m angiogenesis in vivo m Na
+/H
+ APA
IGF-I m EC migration, tube formation m Na
+/H
+ APA
Angiotensin II m gene expression and secretion of VEGF/VPF m Na
+/H
+ APA
PGE2 m EC proliferation Induces i.c. alkalosis
Insulin m EC growth and tube formation m Na
+/H
+ APA
m¼stimulation; EC¼endothelial cell; i.c.¼intracellular; Na
+/H
+ APA¼Na
+/H
+ antiporter activity.
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the Na
þ/H
þ antiporter isoform 3, NHE-3. While it has been
shown to block hydrogen efflux out of the endothelial cell, thus
inhibiting cell alkalinisation and proliferation, some authors
believe that disturbances of cellular pH regulation are not
the basis for the effects of squalamine (Sills et al, 1998). Therefore,
its principal mechanism for blocking angiogenesis still needs
to be elucidated.
Another significant inhibitor of angiogenesis is the drug
amiloride. Amiloride has been advanced to be effective not only
in the experimental treatment of neovascularisation in malignant
tumours but also in chronic proliferative diabetic retinopathy and
in ulcer healing (Sipos and Brem, 2000). As discussed above,
amiloride is thought to inhibit angiogenesis by one, or both, of the
following mechanisms: by blocking Na
þ/H
þ antiporter activity
and/or by inhibiting the mPA–urokinase plasminogen activator
receptor (mPAR) complex.
This group of agents that interact with both angiogenesis and
hydrogen ion dynamics represent a new hope for cancer treatment
(Table 2). Since it is most likely that no single antiangiogenic drug
alone will be effective against all types of tumours, and taking into
account the importance of the relationships between tumour
microenvironment, tumour development, disease progression and
response to therapy, these agents offer additional advantages over
other conventional antiangiogenic drugs apart from the likelihood
of synergy among them. Whichever might be their final mechan-
ism of action as antiangiogenic agents, these drugs appear to
significantly push the tumour milieu towards acidifying tumour
cell pHi and, perhaps also, the pHi of the surrounding cells. Finally,
occasional clinical cases of malignancies successfully treated with
these agents have been reported (Vogt and Frey, 1997; Harguindey
et al, 2002).
CONCLUSIONS AND FUTURE PERSPECTIVES
This short review represents an attempt of an in-depth analysis on
the relationships between two subfields of oncological research
heretofore studied as separate entities: intracellular H
þ dynamics
related to Na
þ/H
þ antiporter activity and angiogenesis research.
The ultimate aim is to both increase the depth of understanding of
the oncogenic process as a whole and, at the same time, to develop
less toxic as well as more effective and selective approaches to the
treatment of malignant diseases. A great deal of both basic and
clinical data support the hypothesis of a key and specific role of
H
þ dynamics in the origin, development, spread and maintenance
of neoplastic disease. In fact, these H
þ dynamics not only
constitute a key hallmark of cancer progression but also determine
the evolution of tumour growth.
As has been reported for other inter-related areas of oncological
research, in the setting of tumour vascularisation, a certain
number of ‘specific’ proangiogenic molecules and antiangiogenic
agents appear to share and function through more encompassing
and nonspecific pivotal and/or common final pathways that
revolve around the regulation of intracellular H
þ dynamics
(Tables 1 and 2). However, more efforts are necessary in order
to unveil the relationships among these fields of oncological
research, starting from their genetic basis and microenviro-
mental conditions to the development of more effective cancer
approaches to the metastatic process, alone or in combination with
standard therapies.
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